News
Investor's Business Daily on MSN4d
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its StockReplimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma ...
Replimune said the agency had issued a complete response letter regarding the company’s biologics license application for RP1 ...
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Replimune Group, Inc. (NASDAQ: REPL) resulting from ...
SAN FRANCISCO, July 23, 2025 (GLOBE NEWSWIRE) -- Investors in Replimune Group, a biotechnology company focused on cancer treatments, witnessed a dramatic collapse in their holdings on July 22. Shares ...
Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.
Replimune Group granted stock options and restricted shares to ten new non-executive employees as part of their incentive plan. Replimune Group, Inc., a clinical stage biotechnology company based ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback